AngioDynamics, Inc. (ANGO) Analysts See $0.17 EPS

December 8, 2017 - By Marie Mckinney

 AngioDynamics, Inc. (ANGO) Analysts See $0.17 EPS
Investors sentiment increased to 2.49 in Q2 2017. Its up 0.91, from 1.58 in 2017Q1. It is positive, as 14 investors sold AngioDynamics, Inc. shares while 27 reduced holdings. 24 funds opened positions while 78 raised stakes. 33.36 million shares or 10.11% more from 30.30 million shares in 2017Q1 were reported.
Zacks Invest Management stated it has 14,145 shares or 0.01% of all its holdings. Sentinel Asset Inc stated it has 861,101 shares. Pnc Financial Svcs Group Inc Inc stated it has 6,155 shares. Royal Fincl Bank Of Canada reported 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Tower Rech Cap Limited Liability Company (Trc) reported 145 shares or 0% of all its holdings. Prelude Capital Management Ltd Llc holds 0.02% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO) for 12,334 shares. Ahl Prns Ltd Liability Partnership holds 54,874 shares or 0.02% of its portfolio. Geode Capital Mngmt Limited Liability Corporation, a Massachusetts-based fund reported 389,831 shares. 116,912 were accumulated by Rothschild Asset Mngmt. Hutchin Hill L P has invested 0.02% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Price T Rowe Assoc Md invested in 14,902 shares. Renaissance Tech Lc reported 0.01% stake. Moreover, Assetmark has 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 188 shares. Tfs Limited Liability Corporation holds 54,355 shares or 0.35% of its portfolio. Spark Investment Lc stated it has 138,500 shares or 0.14% of all its holdings.

Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to report $0.17 EPS on January, 5.They anticipate $0.02 EPS change or 10.53 % from last quarter’s $0.19 EPS. ANGO’s profit would be $6.24M giving it 25.06 P/E if the $0.17 EPS is correct. After having $0.12 EPS previously, AngioDynamics, Inc.’s analysts see 41.67 % EPS growth. The stock increased 0.18% or $0.03 during the last trading session, reaching $17.04. About 208,104 shares traded or 2.46% up from the average. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 31.47% since December 8, 2016 and is uptrending. It has outperformed by 14.77% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 7 analysts covering AngioDynamics (NASDAQ:ANGO), 1 have Buy rating, 0 Sell and 6 Hold. Therefore 14% are positive. AngioDynamics had 18 analyst reports since July 24, 2015 according to SRatingsIntel. As per Tuesday, July 18, the company rating was maintained by Canaccord Genuity. As per Tuesday, November 10, the company rating was downgraded by Raymond James. KeyBanc Capital Markets initiated the shares of ANGO in report on Friday, July 24 with “Overweight” rating. The firm earned “Sell” rating on Monday, August 31 by Zacks. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) has “Equal Weight” rating given on Wednesday, February 8 by Barclays Capital. The firm has “Equal-Weight” rating given on Wednesday, July 19 by Barclays Capital. The stock has “Hold” rating by Canaccord Genuity on Sunday, October 8. The rating was maintained by Canaccord Genuity on Friday, January 8 with “Buy”. Canaccord Genuity maintained the stock with “Hold” rating in Monday, September 4 report. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) earned “Neutral” rating by Sidoti on Wednesday, September 23.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $625.64 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It has a 172.12 P/E ratio. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.